SecBot SecBot
8-K ·Filed Feb 26, 2026

ANIK

Anika Therapeutics, Inc.
MIXED
Impact 6/10
Horizonweeks Processed8mo ago SEC0001193125-26-073401
8-K Item 2.02: Earnings release
Actionable Insight ◆ Mixed

Monitor the execution of cost reduction initiatives ($2.5M annualized EBITDA savings expected) and track OEM Channel pricing stabilization. The CFO transition could create near-term uncertainty, but the reaffirmed guidance and commercial momentum suggest management confidence in 2026 recovery.

DirectionMixed
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$12.79
T+0 close · Feb 26, 2026 · via day close
Latest settled
+17.44%
T+60 · $15.02
Vs SPY
+9.69%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Feb 26 $12.79entry
  2. T+1 · 9mo ago +12.28%α +12.73% · $14.36
  3. T+5 · 9mo ago +11.42%α +12.54% · $14.25
  4. T+20 · 8mo ago +15.32%α +21.73% · $14.75
  5. T+60 · 6mo ago +17.44%α +9.69% · $15.02
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Anika Therapeutics reported flat Q4 revenue of $30.6M but full-year 2025 revenue declined 6% to $112.8M, driven by a 17% drop in OEM Channel sales. The company reaffirmed 2026 revenue guidance of $114-122.5M and announced CFO David Colleran's planned departure in May 2026. Despite improved gross margins and strong commercial channel growth, the negative revenue trend and executive departure outweigh positive operational improvements.

Key Financial Metrics

Revenue
$112.8M
-6.0% YoY
Adj. EPS
$0.11
GAAP: $-0.70
Guidance
$114M-$122.5M
maintained
Free Cash Flow
$4.4M
Gross Margin
57%

Key Facts

  • Q4 2025 revenue: $30.6M (flat YoY), full-year 2025 revenue: $112.8M (down 6% YoY)
  • Commercial Channel revenue grew 22% in Q4 and 15% for full year 2025
  • OEM Channel revenue declined 12% in Q4 and 17% for full year 2025 due to U.S. pricing pressures
  • CFO David Colleran will depart in May 2026 after transition period
  • Company reaffirmed 2026 revenue guidance of $114-122.5M (up 1-9% YoY)
  • Generated $11.2M operating cash flow and $4.4M free cash flow for full year 2025

Financial Impact

Full-year revenue down $7.1M YoY, with $13.4M decline in OEM Channel partially offset by $6.3M increase in Commercial Channel

revenuegross marginoperating cash flow

Segment Breakdown

SegmentRevenueGrowth
Commercial Channel$48.4M+15.0%
OEM Channel$64.4M-17.0%

Risk Factors

  • Continued pricing pressure in U.S. OA Pain Management segment
  • Leadership transition risk with CFO departure
  • FDA approval timeline uncertainty for Hyalofast PMA and Cingal NDA

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-073401
Document: d106406dex101.htm0001193125-26-073401
Document: d106406d8k.htm0001193125-26-073401
Document: 0001193125-26-073401-index-headers.html0001193125-26-073401
Document: 0001193125-26-073401-index.html0001193125-26-073401
Document: 0001193125-26-073401.txt0001193125-26-073401

Track record

13 reports on ANIK

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 6, 202610d ago 8-K Mixed 6/10 Entry $14.55 Now $12.92 −11.20% settles Feb 4
  2. Oct 22, 202625d ago Press Release Neutral 1/10 Entry $21.42 Now $12.92 −39.68% settles Jan 21
  3. Jul 29, 202615w ago 8-K Bullish 8/10 Entry $16.17 to $21.09 Now $12.92 −20.10% ▲ +30.43% +25.70% vs SPY
  4. Jul 14, 202617w ago 8-K Neutral 3/10 Entry $15.93 to $19.23 Now $12.92 −18.90% ▲ +20.72% +18.18% vs SPY
  5. Jun 23, 202620w ago 8-K Neutral 4/10 Entry $14.73 to $21.03 Now $12.92 −12.29% ▲ +42.77% +39.93% vs SPY
  6. Jun 11, 202622w ago Institutional Cluster Bearish 4/10 Entry $14.72 to $21.04 Now $12.92 +12.23% ▼ −42.93% −39.67% vs SPY
  7. Jun 8, 202623w ago DEFA14A Neutral 4/10 Entry $14.60 to $21.11 Now $12.92 −11.51% ▲ +44.59% +41.54% vs SPY
  8. Jun 1, 202624w ago DEFA14A Neutral 3/10 Entry $14.63 to $21.40 Now $12.92 −11.69% ▲ +46.27% +45.04% vs SPY
  9. Apr 30, 202628w ago Insider Cluster Mixed 5/10 Entry $14.85 to $16.17 Now $12.92 −13.00% ▲ +8.89% +7.41% vs SPY
  10. Apr 29, 202628w ago 8-K Mixed 6/10 Entry $12.39 to $14.95 Now $12.92 +4.28% ▲ +20.66% +16.55% vs SPY
Showing 10 of 13

US Market Status

Market Closed · Opens in 5h 51m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Feb 26, 2026